Dovitinib in Adenoid Cystic Carcinoma

Learn more about:
Related Clinical Trial
Drug Screening Using Novel IMD in ACC and Salivary Cancers 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC) AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Understanding the Burden of ACC Through the Eyes of Patients A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Study of Everolimus (RAD001) in Combination With Lenalidomide MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Dovitinib in Adenoid Cystic Carcinoma Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Study of RAD001 in Adenoid Cystic Carcinoma

Brief Title

Dovitinib in Adenoid Cystic Carcinoma

Official Title

Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma

Brief Summary

      The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to
      evaluate the efficacy of TKI258 (Dovitinib).

Detailed Description

      open, uncontrolled, multi-center, phase II study

Study Phase

Phase 2

Study Type


Primary Outcome

progression free survival

Secondary Outcome

 overall survival


Adenoid Cystic Carcinoma


TKI258 (Dovitinib):

Study Arms / Comparison Groups

 TKI258 (Dovitinib)
Description:  TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2011

Completion Date

November 2014

Primary Completion Date

December 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenoid cystic carcinoma

          -  Local, locally advanced or metastatic disease documented as having shown progression
             on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline compared to a
             previous scan taken at any time in the past. Progression must be documented according
             to RECIST criteria.

          -  Disease that is not amenable to surgery, radiation or combined modality therapy with
             curative intent and who is previously treated with chemotherapy or local treatment
             (e.g. transarterial chemoembolization)

          -  Presence of at least one measurable target lesion for further evaluation according to
             RECIST criteria

          -  18 years or older

          -  ECOG performance status 0, 1

          -  Previous treatment with chemotherapy, targeted agents, loco-regional therapy (e.g.
             chemoembolization) are permitted providing that toxicity has resolved to < or = grade
             1 at study entry and that last treatment was at least 4 weeks prior to baseline

          -  Adequate organ function

          -  A patient with the willingness to comply with the study protocol during the study
             period and capable of complying with it

          -  A patient who signed the informed consent prior to the participation of the study and
             who understands that he or she has a right to withdrawal from participation in the
             study at any time without any disadvantages.

        Exclusion Criteria:

          -  A patient with no measurable disease

          -  Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry
             except palliative radiotherapy to non-target lesions (within 2 weeks prior to study

          -  A patient with previous active or passive immunotherapy

          -  A patient with intestinal obstruction or impending obstruction, recent active upper GI

          -  A pregnant or lactating patient

          -  A patient of childbearing potential without being tested for pregnancy at baseline or
             with being tested for positive. (A postmenopausal woman with the amenorrhea period of
             at least 12 months or longer is considered to have non-childbearing potential)

          -  A man or woman of childbearing potential who has no willingness to use a contraceptive
             measure during the study

          -  A patient with history of another malignant disease within past 5 years, except
             curatively treated basal cell carcinoma of skin and cervical carcinoma in situ.

          -  A patient with history of uncontrolled seizures, central nervous system disorder or
             psychiatric disorders that are considered clinically significant by the investigator
             that would prohibit the understanding of informed consent or that may be considered to
             interfere with the compliance of the administration of the study medications.

          -  A patient with clinically significant heart disease (e.g. congestive heart failure,
             symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial
             infarction within past 12 months.

          -  Ongoing cardiac arrhythmia of grade > or = 2, atrial fibrillation of any grade, or QTc
             interval > 450 msec for males or > 470 msec for female.

          -  A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the lungs

          -  A patient with peripheral neuropathy of grade 1 by NCI CTC, caused by other factors
             (e.g. alcohol, diabetes, etc). If the absence of deep tendon reflexes is the only
             neurologic disorder, this condition does not apply to the exclusion criteria.

          -  A patient with organ transplantation requiring immunosuppressive therapy




18 Years - N/A

Accepts Healthy Volunteers



, , 

Location Countries

Korea, Republic of

Location Countries

Korea, Republic of

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Seoul National University Hospital

Study Sponsor

, , 

Verification Date

November 2014